Marizyme Current Valuation vs. Current Ratio
| MRZM Stock | USD 0.05 0.01 25.00% |
For Marizyme profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Marizyme to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Marizyme utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Marizyme's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Marizyme over time as well as its relative position and ranking within its peers.
Marizyme |
Marizyme Current Ratio vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Marizyme's current stock value. Our valuation model uses many indicators to compare Marizyme value to that of its competitors to determine the firm's financial worth. Marizyme is rated top company in current valuation category among its peers. It also is considered to be number one stock in current ratio category among its peers . The ratio of Current Valuation to Current Ratio for Marizyme is about 9,973,164 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Marizyme's earnings, one of the primary drivers of an investment's value.Marizyme Current Valuation vs. Competition
Marizyme is rated top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Information Technology industry is now estimated at about 423.89 Million. Marizyme holds roughly 17.35 Million in current valuation claiming about 4% of equities under Information Technology industry.
Marizyme Current Ratio vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Marizyme |
| = | 17.35 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Marizyme |
| = | 1.74 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Marizyme Current Ratio Comparison
Marizyme is currently under evaluation in current ratio category among its peers.
Marizyme Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Marizyme, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Marizyme will eventually generate negative long term returns. The profitability progress is the general direction of Marizyme's change in net profit over the period of time. It can combine multiple indicators of Marizyme, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida. Marizyme operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 11 people.
Marizyme Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Marizyme. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Marizyme position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Marizyme's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Marizyme without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Breakdown Now
Idea BreakdownAnalyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
| All Next | Launch Module |
Use Investing Themes to Complement your Marizyme position
In addition to having Marizyme in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run High Yield ETFs Thematic Idea Now
High Yield ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Yield ETFs theme has 105 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Yield ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Marizyme OTC Stock
To fully project Marizyme's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Marizyme at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Marizyme's income statement, its balance sheet, and the statement of cash flows.